Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology Inc (NAUT) is advancing proteome analysis through innovative platform technologies that enable groundbreaking research in therapeutic development and medical diagnostics. This news hub provides investors and researchers with essential updates on the company's scientific progress and market developments.
Access authoritative information on NAUT's latest achievements, including product innovations, strategic collaborations, and financial milestones. Our curated collection features press releases covering proteomics advancements, regulatory updates, and technology partnerships that shape the future of precision medicine.
Key content areas include earnings reports, platform technology enhancements, research collaborations, and industry recognition. Each update is carefully selected to reflect NAUT's mission to transform proteomic analysis through its integrated systems and interdisciplinary expertise.
Bookmark this page for streamlined access to NAUT's evolving story in life sciences innovation. For comprehensive insights into the company's role in advancing proteomics research, check back regularly for verified announcements and objective analysis of strategic developments.
Nautilus Biotechnology (NASDAQ: NAUT) has released its Q1 2025 financial results, highlighting progress in their single-molecule proteome analysis platform. CEO Sujal Patel reported positive developments in their Tau proteoform assay, with performance metrics meeting launch specifications and customer requirements.
Key financial highlights:
- Operating expenses: $18.8 million, down 13% from $21.6 million in Q1 2024
- Net loss: $16.6 million, improved from $18.7 million in Q1 2024
- Cash position: $192.8 million in cash, cash equivalents, and investments as of March 31, 2025
The company's cost reduction stems from optimized operations, timing of R&D activities, reduced stock-based compensation, and lower professional services costs. Nautilus aims to enable researchers to study Tau proteoforms in Alzheimer's and other neurodegenerative diseases throughout 2025.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis platform development, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss quarterly results, business developments, and future outlook. Investors can access the live audio webcast through the company's website investor section at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) has released its Q4 and fiscal year 2024 financial results. The company reported Q4 operating expenses of $20.0 million, unchanged from Q4 2023, while full-year operating expenses increased 7% to $81.5 million.
Key developments include:
- Net loss widened to $17.6 million in Q4 2024 and $70.8 million for full-year 2024
- Cash position stands at $206.3 million as of December 31, 2024
- Announced 16% workforce reduction to extend cash runway
- Delayed launch of proteome analysis platform to late 2026
The company expects 2025 operating expenses to be at or below 2024 levels, with current cash reserves projected to sustain operations through 2027.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the TD Cowen 45th Annual Healthcare Conference. The company's management will engage in a fireside chat on March 3, 2025, at 1:50 p.m. Eastern Time.
Investors and interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of www.nautilus.bio. This participation demonstrates Nautilus' continued engagement with the investment community and healthcare sector.
Nautilus Biotechnology (NASDAQ: NAUT), a company focused on single molecule protein analysis platforms, has scheduled its Q4 and full year 2024 financial results announcement for February 27, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss results, business developments, and outlook. Investors can access the live audio webcast through the company's website.
Nautilus Biotechnology (NASDAQ: NAUT) announced that its co-founder and Chief Scientist, Parag Mallick, Ph.D., has been awarded the 2024 Distinguished Investigator Award by the Academy for Radiology and Biomedical Imaging Research. The award recognizes Dr. Mallick's significant contributions to imaging research, including his leadership, high-impact publications, and ongoing research and development work. Dr. Mallick will be inducted into the Academy's Council of Distinguished Investigators during the Annual Meeting of the Radiological Society of North America in December 2024.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has announced its participation in the Inaugural Guggenheim Healthcare Conference. The company's management will engage in a fireside chat on Wednesday, November 13, 2024, at 9:30 a.m. Eastern Time. The presentation will be accessible via live and archived webcast through the 'Investors' section of www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q3 2024 financial results. The company, which focuses on single-molecule proteome analysis platform development, recorded operating expenses of $19.1 million, unchanged from the previous year. The net loss increased to $16.4 million compared to $15.9 million in Q3 2023. As of September 30, 2024, the company maintained a strong financial position with $221.2 million in cash, cash equivalents, and investments.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single molecule protein analysis platforms, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024, before the market opens. The company's management will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss the results, business developments, and future outlook.
Interested parties can access the live audio webcast of the conference call through the 'Investors' section of Nautilus Biotechnology's official website at www.nautilus.bio. This event provides an opportunity for stakeholders and investors to gain insights into the company's financial performance and strategic direction.
Nautilus Biotechnology (NASDAQ: NAUT) has appointed Ken Suzuki as Chief Marketing Officer. Suzuki, a 25-year veteran from Agilent Technologies, brings extensive experience in mass spectrometry and proteomics to Nautilus, a company developing a single-molecule protein analysis platform. This strategic hire comes as Nautilus prepares to launch its Proteome Analysis Platform.
Suzuki's background includes leadership roles in Agilent's Mass Spectrometry division, Strategic Program Office, and Spectroscopy department. His expertise spans marketing, product development, finance, and R&D in the life sciences sector. Nautilus CEO Sujal Patel expressed enthusiasm about Suzuki's potential impact on bringing the company's platform to researchers worldwide.
FAQ
What is the current stock price of Nautilus Biotechnology (NAUT)?
What is the market cap of Nautilus Biotechnology (NAUT)?
